

# PAVE Regional Meeting 2021

## November 30 – December 1

**OBJECTIVE:** the PAVE Regional Meeting aims to promote dialogue between countries on the advances and challenges of expanding *P. vivax* radical cure in the region, gather inputs from regional experts and hear updates on recent research findings on tools and strategies to reach vivax elimination.

### PRELIMINARY AGENDA

#### Day I – November 30, 2021

*All times are in Brasília time (BRT | GMT – 3) – find your local time [on this link](#)*

#### 1:00 – 1:35 PM: Opening

- **1:00- 1:05:** Objectives & Agenda overview – *Elodie Jambert (MMV) & Nick Luter (PATH)*
- **1:05 – 1:20:** Welcome participants
  - *Ray Cummings (PATH)*
  - *George Jagoe (Medicines for Malaria Venture)*
  - *Matt Steele (Bill and Melinda Gates Foundation)*
  - *Alexandra Cameron (Unitaid)*
- **1:20 – 1:35:** Initial remarks – *Ministry of Health representatives*
  - *Cássia Rangel (Department of Immunization and Transmissible Diseases/Brazil's Ministry of Health)*
  - *Representative from Peru's Ministry of Health*
  - *Representative from Colombia's Ministry of Health*

*Facilitator: Jamil Barton (PATH)*

#### 1:35 – 2:15 PM: Radical cure from the regional perspective

- **1:35 – 1:50:** The need for local context-appropriate radical cure to eliminate malaria in the Americas – *Roberto Montoya (Pan-American Health Organization)*
- **1:50 – 2:00:** PAVE in Latin America: framework and in-country partnerships – *Elodie Jambert (MMV) & Nick Luter (PATH)*
- **2:00 – 2:15:** Q&A

*Facilitator: Janice Culpepper (Bill and Melinda Gates Foundation)*

#### 2:15 – 3:10 PM: Safety: How G6PD Testing and Pharmacovigilance can facilitate new treatment options

- **2:15 – 2:25:** Perspectives for qualitative and quantitative G6PD screening: results from the SafePrim study – *José Diego de Brito Sousa (Dr Heitor Vieira Dourado Tropical Medicine Foundation)*
- **2:25 – 2:35:** Perspectives for quantitative G6PD screening: results from the GPOC study – *Stephanie Zobrist (PATH)*
- **2:35 – 2:45:** The Pan-American Health Organization's primaquine pharmacovigilance project – *Sheila Rodovalho (Pan-American Health Organization, Brazil) & Maria Paz Adé (Pan-American Health Organization)*
- **2:45 – 2:55:** The G6PD Educational Pilot Program in Colombia – *Representative from Colombia's Ministry of Health*
- **2:55 – 3:10:** Q&A

*Facilitator: Jonathan Novoa (Medicines for Malaria Venture)*

**3:10 – 3:15 PM:** *Meeting break (please rest without disconnecting)*

**3:15 – 3:50 PM: Efficacy & Effectiveness: Moving toward an optimal deployment of PQ**

- **3:15 – 3:25:** Primaquine 14-day High Dose Clinical Trial in Colombia – *Sonia Herrera (PMI Impact Malaria)*
- **3:25 – 3:35:** Lessons Learned from Peru's transition to primaquine 7-day - *Representative from Peru's Ministry of Health*
- **3:35 – 3:50:** Q&A

*Facilitator: Camilo Manchola (Global Health Strategies)*

**3: 50 – 4:00 PM: Closure of Day I**

- **3:50 – 4:00:** Final remarks for the end of the Day I – *Roberta Ataídes (Global Health Strategies)*

**Day II – December 1, 2021**

*All times are in Brasília time (BRT | GMT – 3) – find your local time [on this link](#)*

**1:00 – 1:05 PM: Opening**

- **1:00 – 1:05:** Welcome participants & agenda overview – *Elodie Jambert (Medicines for Malaria Venture) and Nick Luter (PATH)*

### **1:05 – 1:50 PM: Efficacy & Effectiveness: Looking toward an optimal deployment of TQ**

- **1:05 – 1:15:** Ministry of Health's goals and perspective on pilot implementation of TQ and G6PD test in Manaus and Porto Velho – *Liana Blume (General Coordination of Zoonosis and Vector Transmissible Diseases/Brazil's Ministry of Health)*
- **1:15 – 1:25:** Updates on the TQ feasibility study (TRuST) - *Marcus Lacerda (Dr Heitor Vieira Dourado Tropical Medicine Foundation)*
- **1:25 – 1:35:** The operational feasibility study in Peru: status of protocol development – *Alejandro Llanos Cuentas (Alexander Von Humboldt Institute of Tropical Medicine)*
- **1:35 – 1:50:** Q&A

*Facilitator: Elodie Jambert (Medicines for Malaria Venture)*

### **1:50 – 2:45 PM: Comparing the Costs, Risks and Benefits of radical cure**

- **1:50 – 2:00:** The tafenoquine cost-effectiveness model in Brazil: preliminary results – *Angela Devine (Menzies School of Health Research)*
- **2:00 – 2:10:** The cost-effectiveness and budget impact analysis of radical cure and the quantitative G6PD test in Colombia - *Vívian Velez (University of Antioquia)*
- **2:10 – 2:20:** The estimated impact of tafenoquine for *Plasmodium vivax* control and elimination in Brazil – *Daniel Villela (Oswaldo Cruz Foundation) & Michael White (Pasteur Institute)*
- **2:20 – 2:30:** Risk-Benefit Analysis tool for radical cure – *Michelle Hsiang (University of California, San Francisco)*
- **2:30 – 2:45:** Q&A

*Facilitator: Nick Luter (PATH)*

**2:45 – 2:50 PM:** *Meeting break (please rest without disconnecting)*

**2:50 – 3:35:** **Round table: country perspectives on radical cure and local strategies**

- **2:50 – 3:00:** Liana Blume (General Coordination of Zoonosis and Vector Transmissible Diseases/Brazil's Ministry of Health)
- **3:00 – 3:10:** Representative from Peru's Ministry of Health
- **3:10 – 3:20:** Representative from Colombia's Ministry of Health
- **3:20 – 3:35:** Q&A

*Facilitator: Jonathan Novoa (Medicines for Malaria Venture)*

**3:35 – 4:00 PM: Regional cooperation for radical cure**

- **3:35 – 3:45:** Opportunities for cooperation and partnership in the region - *Maria Paz Adé (Pan-American Health Organization)*
- **3:45 – 4:00:** Wrap up - *Ray Cummings (PATH) and George Jagoe (Medicines for Malaria Venture)*

*Facilitator: Alex Menezes (Global Health Strategies)*